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Abstract: In this review, we discuss the problem of antibiotic resistance, heteroresistance, the 
utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as 
well as the updated treatment strategies for this infection. The prevalence of antibiotic resistance 
is increasing all over the world, especially for metronidazole and clarithromycin, because of their 
heavy use in some geographical areas. Heteroresistance (simultaneous presence of both suscep-
tible and resistant strains in different sites of a single stomach) is another important issue, as an 
isolate could be mistakenly considered susceptible if a single biopsy is used for antimicrobial 
tests. We also examined literature data regarding eradication success rates of culture-guided 
and empiric therapies. The empiric therapy and the one based on susceptibility testing, in Hp 
eradication, may depend on several factors such as concomitant diseases, the number of previous 
antibiotic treatments, differences in bacterial virulence in individuals with positive or negative 
cultures, together with local antibiotic resistance patterns in real-world settings. Updated treat-
ment strategies in Hp infection presented in the guidelines of the Toronto Consensus Group 
(2016) are reported. These suggest to prolong eradication therapy up to 14 days, replacing the 
old triple therapy with a quadruple therapy based on proton pump inhibitor (PPI), bismuth, 
metronidazole, and tetracycline for most of the patients, or as an alternative quadruple therapy 
without bismuth, based on the use of PPI, amoxicillin, metronidazole, and clarithromycin. The 
new drug vonoprazan, a first-in-class potassium-competitive acid blocker recently approved in 
Japan, is also considered to be a promising solution for Hp eradication, even for clarithromycin-
resistant strains. Furthermore, there is growing interest in finding new therapeutic strategies, such 
as the development of vaccines or the use of natural resources, including probiotics, plants, or 
nutraceuticals.
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Plain language summary
In this review, we discuss the issue of an important gastric pathogen, Helicobacter pylori (Hp), 
which has been discovered quite recently in 1983. This microorganism is involved in several 
diseases such as gastritis, peptic ulcer, lymphoma, gastro-oesophageal reflux, and gastric cancer. 
This infection can be permanent in the absence of an appropriate treatment, and Hp intrinsic 
antibiotic resistance is an important obstacle to eradication. 
Hp infection is widespread with about 50% of world population infected. In developing 
countries, especially in lower socioeconomic classes, the prevalence is higher (about 80%), 
whereas in the developed areas such as USA, Canada, Japan, and Western Europe, the prevalence 
is much lower (about 25%–30%). Therefore, it is crucial to identify effective therapies capable 
of curing Hp infection. We reviewed literature data searching for the best options to eradicate 
this pathogen that ensure both patients’ compliance and the fewest side effects.
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Introduction
Helicobacter pylori (Hp) is a Gram-negative mobile bacillus, 
difficult to be cultured, which has been reported to be geneti-
cally extremely variable, and this heterogeneity is proposed 
to be involved in its ability to cause different diseases, detri-
mental and nondetrimental chronic infections.1,2 As a matter 
of fact, Hp is involved in a wide variety of infections such as 
chronic active gastritis, peptic ulcer disease, gastric carcinoma, 
and mucosa-associated lymphoid tissue (MALT) lymphoma. 
Furthermore, epidemiological and eradication studies have 
demonstrated a causal relationship between Hp infections and 
endothelial dysfunction leading to vascular diseases.3,4
Usually, the colonization occurs primarily during child-
hood, especially in the developing areas, predominantly in 
the same family as a consequence of cohort effect.5 This 
colonization is widely asymptomatic even if a long-lasting 
infection can be established in some subjects. Although 
the prevalence of Hp seems to decrease in some parts of 
the world, the presence of this infection remains high in 
some populations ranging from 25% to 86%, depending 
on the areas under consideration. According to the Center 
for Diseases Control in USA (www.cdc.gov/ncidod/dbmd/
hpylori.htm), about 50% of the world population is infected 
with Hp.6–8 Generally, the prevalence of infection is more 
closely correlated with socioeconomic conditions than with 
geographic origin. For what concerns industrialized countries, 
the prevalence is 20% of the population under 40 and 50% of 
people over 60, whereas it is rare in children. A low socio-
economic status and a large flux of immigrants represent risk 
factors for the infection in these settings. On the contrary, 
in developing countries, infection involves the majority of 
the adult population (about 80%) and 10% of children from 
2 to 8 years old. The prevalence of Hp infection in the white 
population of USA and South Africa is almost comparable 
to that of Europe, whereas other ethnic groups have double 
prevalence values.9 More virulent strains (CagA + and 
VacA +) have been found in the general male population in 
the UK reaching up to 44% of the tested individuals and even 
more in a previous epidemiological survey in Italy regarding 
a population of military students.10,11
Infection is virtually lifelong in the absence of treatment, 
implying that evasion of the host response is efficient.
Hp antibiotic resistance is a primary hurdle to achieving 
eradication. Treatment regimens that have been used over the 
past decade are declining in efficacy, and the treatment of this 
infection is bedeviled by drug-resistant strains. The leading 
causes of treatment failure are antimicrobial resistance and 
nonadherence to therapy (poor patient compliance).
Hp is described as a microorganism that can easily acquire 
resistance to antimicrobial agents leading to increased preva-
lence of antibiotic-resistant strains, thus reducing success 
with traditional therapies.12 The acquired resistance can be 
due either to antibiotic consumption in individual lifetime 
or to repeated therapeutic attempts.13 Susceptibility testing 
should be then the method of choice in guiding the most 
appropriate cure.14
The goal of Hp therapy should be the achievement of 
eradication in about 90% of treated patients but this result 
is hardly reached.15
The aim of the present review is to discuss the results of 
the sensitivity in vitro of the most common antibiotics, the 
presence of heteroresistance (HR) in different infected parts 
of the single stomach, the value of cultures and antibiotic 
susceptibility tests in the eradication rate, as well as updated 
treatment strategies.
Susceptibility to antibiotics
The most common antibiotics used in Hp treatment are the 
following: metronidazole (MZ), clarithromycin (CLA), 
amoxicillin (AMX), tetracycline (TE), levofloxacin (LEV). 
The resistance rates vary widely depending on geographical 
areas, so that therapy should be tailored according to regional 
antibiotic resistance patterns and individual characteristics. 
At the beginning of the 1990s, a low prevalence of CLA 
resistance was detected ranging from 1% to 8%, whereas 
MZ resistance resulted to be stable over time ranging from 
20% to 40%. The resistance to AMX resulted to be very low 
(1%–3%).16–18 In the last years the prevalence of CLA and 
MZ secondary resistance has become very high (67%–82% 
for CLA and 52%−80% for MZ).19
The patterns of resistance to antimicrobials may change 
over time, considering that in countries where CLA resis-
tance is progressively higher, there is a subsequent use 
of MZ-based therapies, which leads to an increase in MZ 
resistance. Hp may acquire resistance to rescue antibiotics 
during the course of eradication therapies or treatments of 
other bacterial infections, thereby becoming multiresistant 
and difficult to remove.15,20
Bacterial antibiotic resistance can be classified as intrinsic 
or acquired resistance; the first is a genetic property for most 
bacterial strains and typically evolves regardless of clinical 
use of antibiotics; the latter implies that a susceptible organ-
ism has developed resistance to antimicrobial agents to which 
it was previously susceptible.21,22
A) Resistance to MZ: MZ resistance is due to point mutations 
regarding rdxA and frxA genes that prevent intracellular 
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activation of the drug by inhibiting the nitroreductases, 
which activates the prodrug (a synthetic nitroimidazole) 
in its active form within the cytosol of the bacterial cells.23 
MZ resistance is a frequent issue in various geographi-
cal areas because of epidemic diseases (eg, amoebic, 
gynecological, and anaerobic infections) endemic in 
different countries. In vitro results often do not correlate 
with in vivo efficacy. The E-test has been established as a 
reliable method for measuring antibiotic resistance to all 
antimicrobials in vitro, except for MZ for which it overes-
timates the resistance. This discrepancy between in vitro 
MZ resistance and treatment outcome may partially be 
explained by changes in oxygen pressure in the gastric 
environment, as MZ-resistant Hp isolates become MZ-
susceptible under low oxygen conditions in vitro.24 The 
role of these inactivating mutations on the reversibility 
of MZ resistance under low oxygen conditions is well 
established. In fact, it has been found that under anaerobic 
as well as microaerophilic conditions, all isolates lose 
their MZ resistance, while no effect is seen with other 
antibiotics used in Hp treatment such as AMX, TE, and 
LEV.24 The resistance to MZ is quite high in almost all 
studied countries. Li et al25 found 75.2% of resistance rate 
in a population of children in People’s Republic of China. 
In Morocco, the rate was 40%, in the USA it ranged from 
20% to 40%, in central Italy (Abruzzo) it was 34.69% in 
gastric antrum and 42.16% in fundus.26–28 Only a multi-
center study conducted in Northeast Italy by Pilotto et al29 
found a resistance rate as low as 14.9%. In any case, a 
higher resistance rate has been detected in developing 
countries (50%−80%) such as Mexico (about 77%).30 
In Japan and in Canada the prevalence was 9%−12% 
and 18%−22%, respectively.31,32 These differences are 
probably due to an extensive use of MZ in each country. 
In fact, an earlier use of this drug is associated with an 
increase in MZ resistance.33
B) Resistance to CLA: CLA resistance is due to point muta-
tions in the 23S rRNA genes (ie, A2143G and A2142G). 
These mutations prevent the macrolide from binding to 
the 50S ribosomal subunits.34 Resistance to CLA has 
been studied on a large scale because of the fact that it 
has been considered the antibiotic of choice over the last 
years. The local pattern of Hp resistance to CLA results 
to be crucial in each country, taking into account that 
in countries where CLA resistance is above 15%–20%, 
this drug should not be used. CLA-resistant Hp has been 
extensively studied: its prevalence has become increas-
ingly higher in many geographical areas. Resistance to 
CLA depends on the local Hp seropositivity rate. This 
means that in regions with a low prevalence of Hp, anti-
biotic resistance seems not to increase over time, whereas 
in regions with a high prevalence of infection, a high 
increase of antibiotic resistance related to the rise of Hp 
seropositivity is detected.35,36 For instance, in People’s 
Republic of China, an increase of CLA resistance from 
15% in 2000 to 53% in 2014 was accompanied by a rise in 
seropositivity rates from 65% to 83%.37–39 In contrast, in a 
multicenter retrospective study of children population in 
People’s Republic of China, the pattern of Hp antibiotic 
resistance showed no significant changes in the resistance 
rates to CLA, AMX, furazolidone, and MZ over 7 years. 
The age of children slightly affected the resistance rates 
to CLA and MZ.25
Similarly in Japan, an increase in CLA resistance 
ranging from 1.8% in 1996 to 27.1% in 2008 has been 
described.36 In Korea, CLA resistance increased from 
11% in 2005 to 60% in 2009.40 In Morocco (Rabat) the 
prevalence of primary resistance to CLA was 29% with 
2% of strains showing double resistance to MZ and CLA 
at the same time.26 In Central Italy, Di Giulio et al28 per-
formed a study involving nine antibiotics, which showed 
an overall CLA resistance rate of 72.44% in gastric antrum 
and 72.8% in fundus, concluding that the high rate of 
resistance to CLA and also to MZ (34.69% in antrum and 
42.16% in fundus) as well as to quinolones (42.85% and 
53.01% in antrum and fundus, respectively) might reflect 
their overuse. In the USA there is an increase of CLA 
resistance as well.27 In a study on a pediatric population 
in the USA, the resistance rate was as high as 50%.41
The varying distribution of CLA resistance in differ-
ent geographical areas raises the issue of an accurate study 
of the local situation of antibiotic resistance in order to 
better guide treatment regimens.
C) Resistance to AMX: Resistance to AMX is due to altera-
tions of penicillin-binding proteins and to decreased 
antibiotic membrane permeability in the cytosol of 
bacterial cells (active efflux pump that excretes drugs).42 
AMX resistance results to be very low in most countries 
being ,2% in Europe (Germany and the Netherlands) 
and higher (up to 38%) in Asia and South America.43–46 
In People’s Republic of China it has been detected in 
only 0.06% of the population.25
D) Resistance to TE: The mechanism of TE resistance is 
based on the inhibition of protein synthesis through 
binding to the 30S subunit of ribosomes, thus blocking 
the synthesis of nascent peptide chains.47 Resistance 
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to TE is very low (0.7%−1%) or even absent in most 
countries.48,49
E) Resistance to LEV: Point mutations of gyrase A coding 
for DNA gyrase are involved in LEV resistance.50 There 
is a limited number of studies evaluating susceptibility 
to LEV. In Italy LEV resistance has been reported to be 
22%–24% similarly in Portugal.51,52 In People’s Republic 
of China, in a multicenter, retrospective study of Chinese 
children, the resistance rates were lower, accounting for 
6.7% of the study population.25 LEV resistance rate of 
11% was detected in Morocco by Bouihat et al26 in a 
multicenter study of patients referred for gastroduode-
nal endoscopy who had never been treated previously. 
Anyway, there is concern that LEV resistance may 
increase in many countries.53–55
Taken together these data show that resistance to different 
antimicrobial agents varies greatly all over the world based 
on comorbidities, previous diseases, age, socioeconomic 
conditions, the number of eradication therapy cycles, the use 
and overuse of antibiotics, as well as the period of time in 
which the study was conducted. It is important to highlight 
all these variables in order to obtain a general view of the 
current situation in each country.
In our research conducted at the University Hospital in 
Rome, 61 strains were isolated from 50 patients affected with 
pangastritis who underwent at least two or more eradication 
cycles (up to nine). We have observed a higher resistance rate 
compared to other national studies performed in patients with 
different pathologies and no previous therapeutic regimens. 
As shown in Table 1 (Mascellino, unpublished data, 2013), 
the values of minimum inhibitory concentrations (MICs) of 
the tested antibiotics determined by E-test and relative rates 
of resistance regarding our patients are reported. Resistance 
to MZ was up to 82% and that to CLA reached 54%. These 
strains appear to be highly resistant to MZ with three strains 
showing an MIC value .256 mcg/mL. AMX is the most 
effective antibiotic as well as TE (5% and 7% of resistance, 
respectively). Resistance rate to LEV was 25%. Double 
resistance to MZ and CLA, which can be demonstrated in 
about half of the strains under study, may lead to a worse 
course of the disease and poor eradication outcome.
We have detected higher resistance rates compared to other 
studies, especially for CLA and MZ. In fact, in one survey 
taking into consideration a Polish population studied in 2014 
(adult symptomatic patients with primary infection), among 50 
Hp strains, 12 (24%) were resistant to CLA, 21 (42%) to MZ, 
and 4 (8%) to LEV. Examined strains were fully susceptible 
to AMX and TE. Moreover, the authors found a different 
sensitivity to CLA and MZ, according to patients’ age (the 
highest CLA resistance was found in younger individuals, 
whereas the resistance to MZ increased with age).56
The discrepancy between the results of our preliminary 
research and the Polish study may be due to the differences 
between the study populations. In fact, in our case, patients with 
previous eradication failures were taken into consideration. 
In this setting, strain isolates can acquire higher resistance, 
considering that pangastritis patients are the most difficult to 
cure. In fact, in this selected population, Hp infection is quite 
characteristic, as the bacteria are capable of colonizing the 
entire stomach in the condition of reduced acid secretion. Thus, 
the mechanisms of virulence and persistence may be different 
compared with patients with normal acid secretion.57
Heteroresistance
HR is defined as the coexistence of susceptible and resistant 
isolates in the same patient for the same antimicrobial agent. 
This is a common occurrence in Hp population and can be 
explained either as the result of multiple infections (unrelated 
isolates) or as the presence of susceptible and resistant vari-
ants of the same strain (related isolates). In the latter case, HR 
has been described either as intradistrict when susceptible 
and resistant isolates are present at the same time in the same 
site of gastric mucosa or as interdistrict when multiple strains 
colonize different areas of the stomach.21,58–60 For this reason, 
Table 1 Sensitivity testing and MiC values distribution with e-test method for 61 Helicobacter pylori strains isolated in 50 pluri-treated 
pangastritis patients who underwent two to nine therapy cycles (Mascellino, unpublished data, 2013)
Antimicrobial 
agents
MIC values MIC break 
points
Resistant 
strains, 
N (%)
Susceptible 
strains, 
N (%)#0.12 #0.25 #1 #8 8–32 64–128 $256 S# R.
MZ 0 0 5 6 33 14 3 8 8 50 (82) 11 (18)
CLA 4 24 8 12 7 6 0 0.25 0.5 33 (54) 28 (46)
Lev 8 32 6 10 4 1 0 1 1 15 (25) 46 (75)
Te 25 22 10 3 1 0 0 1 1 4 (7) 57 (93)
AMX 58 2 1 0 0 0 0 0.12 0.12 3 (5) 58 (95)
Notes: Total 61 strains. The antibiotic breakpoints are calculated following eUCAST 2016.
Abbreviations: AMX, amoxicillin; CLA, clarithromycin; EUCAST, The European Committee on Antimicrobial Susceptibility Testing; LEV, levofloxacin; MIC, minimum 
inhibitory concentration; MZ, metronidazole; R, resistant; S, susceptible; Te, tetracycline.
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data regarding HR indicate that no single biopsy site can be 
considered representative of antimicrobial susceptibility test-
ing and that this peculiarity can lead to underestimation of 
antimicrobial resistance as its detection is more difficult when 
Hp is not uniformly distributed in the stomach.60 It should be 
considered that in patients with pangastritis, biopsies for Hp 
culture and susceptibility testing should be obtained from all the 
gastric regions, in order to obtain a full view of the inflamma-
tion status and to verify the presence of HR to antibiotics.57
Several articles report the phenomenon of HR in Hp 
infection. Ben Mansour et al61 have studied this issue on a 
large scale distinguishing between multiple infections with 
genetically different isolates based on genotyping of viru-
lence genes (cagA and vacA) and mixed infections where 
both antibiotic-susceptible and -resistant isolates belonged 
to the same genotype detected by a random amplified poly-
morphism DNA (RAPD profile). It has been reported that 
in mixed infections a resistant clone emerges from the sus-
ceptible one under selective pressure because of antibiotic 
consumption, whereas in multiple infections the individual is 
infected by two genetically distinct strains. In the first case, 
discordant results of susceptibility testing were detected in 
two biopsies from the same patient. The same authors studied 
Hp infection in populations in two different geographical 
areas: in Tunis with a prevalence of Hp infections of about 
50% and in Poitiers in France with a prevalence of 22%.61 
It has been reported that multiple infections are more frequent 
in developing areas such as Tunis, whereas mixed infections 
are more frequently detected in developed countries, prob-
ably due to increased consumption of antibiotics in this area.62 
Multiple infections facilitate interstrain gene transfer and 
maintenance of genetic diversity. Instead, in mixed infections 
(susceptible and resistant strains at the same time), the resis-
tant genes such as rdxA and frxA for MZ, 23S rRNA for CLA, 
and gyrA for LEV are not detected by RAPD-polymerase 
chain reaction (PCR). Thereby, both susceptible and resistant 
strains may express an identical genetic profile mainly in 
patients with single infection (unique RAPD fingerprint).63 
Mixed infections may represent a major challenge, because 
when only few resistant strains are present in a population of 
susceptible isolates, the resistant bacteria cultures are difficult 
to be carried out especially by phenotypic tests.64,65 This kind 
of problem emerges more frequently for MZ, probably due 
to a higher prevalence of MZ resistance.
Kim et al66 examined 220 pairs of isolates obtained 
from both antrum and corpus and found that 41 out of 109 
patients (38%) showed HR in two biopsy sites and that 34% 
with resistant strains would be misclassified as susceptible 
if a biopsy of the antrum alone was used for antimicrobial 
susceptibility testing. It is suggested that the development 
of resistance is most likely caused by genomic alterations 
from pre-existing susceptible Hp rather than by a coinfection 
with a different strain. Furthermore, there is a possibility that 
genomic DNA from a resistant Hp can transform a suscep-
tible strain into a resistant one.
de la Obra et al21 found cultures containing mixed, 
MZ-susceptible and MZ-resistant isolates in 10% of cases. 
Considering the genetic relationship of the isolates showing 
HR, it can be highlighted that MZ resistance can be due to ex 
novo mutations (acquired resistance) and not to the horizontal 
transfer of genes among unrelated strains.
The results of our study, as reported in Table 2, showed 
that in the patients with HR, each pair of isolates in different 
gastric regions (antrum and corpus) belonged to the same 
genotype (cagA + s1m2 in one patient and cagA + s1m1 in 
three patients).67 Yet, other authors share the opinion that an 
individual may have a mixed Hp infection, as demonstrated 
by the presence of different antimicrobial susceptibility in 
various gastric regions contemporarily harboring the same 
genotype.68
Norazah et al69 showed that some isolates with similar 
PCR-RAPD differed in their antibiotic profiles because of 
MZ resistance in one of the stomach sites. A large degree 
of genetic heterogeneity was observed in H. pylori strains 
circulating among Malaysian patients. The phenomenon of 
HR predominantly involves MZ and CLA.
Table 2 Heteroresistance of Helicobacter pylori isolates to CLA, MZ, and AMX in four patients, in different districts of the stomach
Antibiotics Patient 1 Patient 2 Patient 3 Patient 4
CLA
Both pairs in A–C Genotype
S (C)  R (A)
cagA + s1m2
S (C)  R (A)
cagA + s1m1
S (C)  R (A)
cagA + s1m1
S (C)  R (A)
cagA + s1m1
MZ
Both pairs in A–C Genotype
S (A)  R (C)
cagA + s1m1
AMX
Both pairs in A–C Genotype
S (C)  R (A)
cagA + s1m1
Notes: The strain genotypes, detected on the basis of virulence genes (cagA and vacA) in both pairs of isolates from different parts (antrum and corpus) in a single stomach, 
are the same in each site (cagA + s1m2 in one patient and cagA + s1m1 in three patients). The genotype cagA + s1m1 results to be more virulent than the genotype 
cagA + s1m2.67
Abbreviations: A, antrum; AMX, amoxicillin; C, corpus; CLA, clarithromycin; MZ, metronidazole; R, resistant; S, susceptible.
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The resistance studied through a real-time PCR with 
hybridization probes has been mainly focused on CLA and 
TE.65,70 Conventional antimicrobial susceptibility testing 
(E-test) fails in ~10% of attempts because of the overgrowth 
of contaminating bacteria or to the lack of live microor-
ganisms. As previously demonstrated for CLA, molecular 
techniques such as a real-time PCR can be used as a diagnos-
tic rescue method.65 Thus, this assay proved to be reliable and 
quite sensitive in diagnosing resistant bacteria. As a matter of 
fact, some differences in the detection of antibiotic resistance 
may be observed in several strains when comparing E-test 
with PCR, especially if there are only few resistant bacteria 
among many susceptible ones. In this condition, the resistant 
bacteria are difficult to detect. Through phenotypic testing 
(E-test), the susceptible bacteria are identified first leading 
to a possible misclassification, whereas with real-time PCR 
a mixed infection with both resistant and susceptible strains 
is easily detected. In our study, 44 patients (71%) out of 62 
with Hp infection were found to yield both wild types and 
strains carrying the mutation A21444G for CLA. Among 
these 44 individuals, 34 (77.2%) showed susceptibility and 
only 10 (28%) resulted to be resistant by E-test, whereas all 
44 strains showed resistance to CLA by PCR.57
However, we should consider some issues because of 
the use of molecular methods. First of all it is necessary to 
highlight that the Hp culture with antibiotic susceptibility test 
remains the gold standard in the detection of this microorgan-
ism as well as of most of the bacteria in clinical practice.71 
Thus, the importance of H. pylori culture remains unaltered 
both in epidemiological and pharmacological fields. More-
over, the culture is crucial in the identification of new drugs 
for Hp in different countries as well as in the preparation for a 
future vaccine. Rather the problem concerns the difficulty of 
Hp growth that is slow and time consuming and not available 
for all routine diagnostic laboratories.
Other shortcomings of the PCR assay might be its low 
specificity for Hp or the presence of false negative even 
though these problems seem to be overcome by the updated 
methodologies.65,70 In fact, on one hand, Oleastro et al65 state 
that their assay to test CLA resistance compared to the real-
time PCR assays previously reported in the literature proved 
to be able to detect all the common mutations associated 
with CLA resistance, whereas the assay described in 2001 by 
Chisholm et al72 appeared to be less sensible (four biopsies 
out of 56 were found to be falsely Hp negative).
On the other hand, Glocker et al70 show that, although 
the PCR primers applied for the detection of TE resistance 
are not specific for Hp, melting curve analysis allows 
discrimination between H. pylori and other Helicobacter 
species and recommend in order to exclude false positive, 
that all samples be tested by an Hp specific PCR assay (ie one 
that amplifies the vacA or ureC gene).
All in all, we can say that the real-time PCR should be 
used in case of growth failure, contamination, and mixed 
infections, thus obviating the need of live bacteria other than 
on gastric biopsy samples. In the latter case it would be pos-
sible to detect directly from the biopsy the CLA genotypic 
resistance that could predict possible therapy failures or 
cause changes in the previous treatments.70,73 The genotypic 
resistance determined using stomach specimens correlates 
well with the genotypic and phenotypic resistance determined 
in Hp strains.73 More importantly, this molecular assay 
can be conducted using stool samples without performing 
endoscopy.74 In these situations PCR proves to be superior 
to bacterial culture.
To the best of our knowledge, there are not sufficient data 
in the literature in support of the fact that HR may, on large 
scale in clinical practice, affect Hp eradication outcomes. 
The current guidelines for Hp treatment do not issue any 
statements in this regard.
Value of culture and antibiotic 
susceptibility testing in the 
eradication rate
The resistance of Hp to antibiotics has become more preva-
lent over time so that culture-guided therapies result in a 
significantly lower risk of treatment failure compared with 
empiric standard triple therapy. Antimicrobial susceptibility 
testing has, therefore, been proposed as a logical first step 
in treatment failure (the goal in fact is to cure the infection 
after having obtained the result of antibiotic susceptibility 
test) but controlled trials suggested that it may not always 
be essential for clinical management.75,76
The question whether susceptibility testing is essential 
in guiding therapeutic strategies has been debated in many 
studies. Some data show that successful eradication can be 
achieved in almost all patients without susceptibility test-
ing, whereas the results of other studies demonstrate that 
even a first-line therapy should rather be scheduled on the 
basis of sensibility/resistance of Hp to antibiotics.73,77–79 
Making comments on susceptibility-based therapies, Graham 
highlights that they will always be superior to empiric thera-
pies in any population with the prevalence of antimicrobial 
resistance .0%.78 The problem of antibiotic susceptibility 
has mainly economic implications. Susceptibility testing 
is expensive and time consuming, not available in many 
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hospitals and being mostly reserved to a limited number of 
selected patients attending dedicated centers. Furthermore, it 
would not be possible to perform susceptibility tests in many 
patients who refuse to undergo endoscopy for its invasive-
ness and costs.
This issue has been studied in our Institution. From 2011 
through 2013, we evaluated 100 patients with previous two 
or more therapeutic treatments, all positive on C13 urea 
breath test (UBT) and histological examination.57 Sixty-
two out of 100 subjects showed positive culture and were 
treated according to antibiotic-susceptibility tests generally 
with the standard triple therapy containing lansoprazole + 
AMX and either MZ or CLA (LAC or LAM). The remain-
ing 38 patients showed no microorganism growth and thus 
underwent tailored empiric therapy using antibiotics not used 
before and the time of cure was prolonged. We observed 
that patients treated empirically showed a degree of eradi-
cation of 84% and the patients with positive cultures and 
susceptibility-based treatment, of 77%. This can be due to 
the fact that bacteria unable to grow on culture media were 
probably fewer (too low in number to be cultured) and in 
a less virulent or dormant phase compared to the patients 
where Hp was isolated.57
Many variables are involved in this issue and for this 
reason no uniform and homogeneous data can be found in 
the literature. In fact, on one hand, culture-guided therapy is 
essential in order to establish a correct and efficacious treat-
ment, and on the other hand it is also reported that empiric 
therapy based on regional antibiotic resistance patterns 
achieves high eradication rates.78–81 It would be possible to 
predict the efficacy of any treatment knowing the prevalence 
of antibiotic resistance for a regimen or even for a specific 
patient: as a matter of fact empiric therapy that takes into con-
sideration the regional and mostly the local resistance patterns 
may be superior to predict the efficacy of any regimen.23,80 
Hence, the regional resistance patterns and the eradication 
rates in the context of local environment are crucial for a 
correct establishment of Hp cure in real-world settings.
Previous regimens and updated 
treatment strategies
Previously empirically tailored triple therapy was suggested 
with the association of two antibiotics: AMX (1 g) due to 
its low rate of resistance and either MZ (250 mg) or CLA 
(250 mg) given b.i.d. for 10 days combined with PPI (proton 
pump inhibitor 40 mg) considering the gastritis pattern.82,83 
In patients with MZ-resistant strains, this drug was admin-
istered at a higher dosage of 500 mg b.i.d. Indeed, there is 
evidence that the increase in MZ dosage generally improves 
the results of therapy when treating MZ-resistant Hp strains. 
It is confirmed that the proportion of eradication rate is sig-
nificantly lower in resistant compared to susceptible strains 
especially with triple therapy. The eradication success rate 
with quadruple therapy including MZ appears to be lower 
in MZ-resistant versus MZ-sensitive strains (92% versus 
80%), p=0.06.84,85
The knowledge of the local antibiotic resistance is crucial 
in order to establish an appropriate antibiotic therapy. It is 
reported that the increasing prevalence of CLA resistance 
is the main factor contributing to Hp treatment failure 
indicating that in the regions with CLA resistance .15%, 
a regimen including CLA should not be used.84,86,87 The old 
triple therapy (PPI + AMX and either CLA or MZ) should 
be considered only in areas where resistance to CLA is low 
(,15%) or where a high eradication success rate with these 
regimens (.85%) is well known.84 In general, in Western 
countries, CLA-containing triple and sequential therapies 
should be considered obsolete as empiric treatment.83 
Sequential therapy has been first introduced by Zullo et al 
and consists of 10-day therapy comprising 5 days of PPI + 
AMX followed by other 5 days with triple treatment contain-
ing PPI + CLA + MZ.88 This regimen uses AMX first as it 
is able to overcome CLA resistance by destroying Hp cell 
walls and preventing activation of efflux channels, which is 
one of the mechanisms for CLA resistance. Unfortunately, 
this kind of therapy decreases patients’ compliance.
Concomitant therapy includes PPI, CLA, AMX, and 
MZ for at least 10 days. This regimen has shown a better 
outcome over standard triple therapy especially in cases of 
CLA resistance. The advantages of concomitant therapy 
are the efficacy against dual antibiotic-resistant strains and 
a higher compliance rate compared with the sequential 
therapy.89,90 Anyway the efficacy of concomitant therapy 
depends on the prevalence of Hp antimicrobial resistance, 
which varies in geographical areas. The updated guidelines 
for Hp treatment recommend to prolong therapy from 
10 to 14 days. For the first-line treatment, a concomitant 
non-bismuth quadruple therapy (PPI + AMX + MZ + CLA, 
PAMC) or traditional bismuth quadruple therapy (PPI + 
bismuth + MZ + TE, PBMT) is recommended. Bismuth qua-
druple therapy is unaffected by CLA resistance.84 In a recent 
survey conducted in Italy in 2016, Tursi et al91 described the 
first Italian experience in clinical practice with this new bis-
muth-containing quadruple therapy in patients infected with 
Hp. Both naïve and previously treated dyspeptic patients were 
enrolled. This new therapy seems to be a more reliable option. 
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Patients were treated with a new formulation of drugs that 
uses a single pill (three in one capsules containing bismuth 
subcitrate potassium 140 mg, MZ 125 mg, and TE 125 mg). 
Three capsules q.i.d. plus omeoprazole 20 mg or esome-
prazole 40 mg b.i.d. are given for 10 days.91 Hp eradication 
rate assessed with UBT resulted to be very high: 94.7% in 
intention-to-treat (ITT) analysis, whereas in the per protocol 
(PP) population this percentage was even higher (97.6%). 
No difference was seen in the group studied by Tursi et al91 
between naïve population and previously treated patients. 
This new bismuth-containing quadruple therapy results to be 
very effective in both situations: as the first-line treatment and 
as rescue therapy. However, in this survey, some limitations 
may be present considering the small number of individuals 
enrolled and the fact that this therapy has become available 
in Italy only in 2016. No antibiotic tests were performed in 
the population under study. Nevertheless, the eradication 
rates were very high.91
Likewise, recently, Delchier et al91 found that this new 
regimen used as a rescue therapy reached an eradication rate 
in ITT and PP populations, of 93% and 95%, respectively, 
showing comparable results with those obtained by Tursi.92 
All current guidelines advice to prescribe bismuth-based 
regimens in areas where resistance to CLA is high.
Beyond the quadruple therapy, recommended rescue 
therapies also include treatments based on the use of LEV (PPI + 
AMX + LEV, PAL). An appropriate second-line regimen 
should contain a quinolone; however, there is little research 
to support this, and it should be noted that many regions 
have high quinolone resistance rates.93 The use of rifabutin 
(RIB) (usually PPI + AMX + RIB, PAR) should be limited 
to patients who failed at least three previous regimens as 
reported by Fallone et al84 (Table 3). Moreover, the Toronto 
guidelines discourage the addition of probiotics for the 
reduction of side effects of the therapy or for increasing 
the eradication rates because the evidence in support of this 
thesis is very limited.84 The Toronto Consensus Group for the 
treatment of Hp infection concluded that the treatment choice 
must be based on the susceptibility tests but above all, on the 
prevalence of antibiotic resistance as well as on eradication 
patterns of specific therapies in the local population. When 
this information is not available, the empiric alternative for 
adults includes quadruple therapies PAMC or PBMT for 
14 days.85 The strategy is directed to various use and con-
sumption of antibiotics in different geographical areas over 
time. This means that the choice of a second-line treatment 
depends on previous antibiotic exposure. In fact, the selec-
tion pressure exerted at a population level with a high use of 
antimicrobial agents will be the reason for the emergence and 
spread of resistance in the population and a high incidence 
of primary resistance.61
A new drug, vonoprazan (potassium-competitive acid 
blocker P-CAB), recently approved in Japan, has become 
available for Hp treatment even for CLA-resistant strains. 
Table 3 Recommendations for regimens used for the eradication of Helicobacter pylori
Recommendation Regimen Definition
First line
Recommended option Bismuth quadruple (PBMT) PPi + bismuth + metronidazolea + tetracycline
Recommended option Concomitant non-bismuth quadruple (PAMC) PPi + amoxicillin + metronidazolea + clarithromycin
Restricted optionb PPi triple (PAC, PMC, or PAM) PP1 + amoxicillin + clarithromycin
PPi + metronidazolea + clarithromycin
PPi + amoxicillin + metronidazolea
Not recommended Levofloxacin triple (PAL) PPi + amoxicillin + levofloxacin
Not recommended Sequential non-bismuth quadruple (PA followed 
by PMC)
PPi + amoxicillin followed by PPi + metronidazolea + 
clarithromycin
Prior treatment failure
Recommended option Bismuth quadruple (PBMT) PPi + bismuth + metronidazolea + tetracycline
Recommended option Levofloxacin-containing therapy (usually PAL) PPi + amoxicillin + levofloxacinc
Restricted optiond Rifabutin-containing therapy (usually PAR) PPi + amoxicillin + rifabutin
Not recommended Sequential non-bismuth quadruple therapy (PA 
followed by PMC)
PPi + amoxicillin followed by PPi + clarithromycin + 
metronidazolea
Undetermined Concomitant non-bismuth quadruple therapy (PAMC) PPi + amoxicillin + metronidazolea + clarithromycin
Notes: Reprinted from Gastroenterology, 151(1), Fallone et al, The Toronto consensus for treatment of Helicobacter pylori infection in adults, 51–69, Copyright (2016), with 
permission from elsevier.84 aTinidazole may be substituted for metronidazole. bRestricted to areas with known low clarithromycin resistance (,15%) or proven high local 
eradication rates (.85%). cThere is some evidence that adding bismuth to this combination may improve outcomes. dRestricted to cases in which at least three recommended 
options have failed.
Abbreviation: PPi, proton pump inhibitor.
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It is used for both, primary and secondary eradication, thereby 
addressing the health care needs in acid-related disorders.94
Vonoprazan could improve eradication rates by raising 
the intragastric pH and thus increasing bacterial antibiotic 
susceptibility. Recent studies revealed that P-CAB-based 
triple therapy was more effective than PPI-based triple 
therapy (76.1% versus 40.2%) as a first-line Hp eradication 
method.95–97 Furthermore, even in the presence of CLA-
resistant strains, P-CAB-based triple therapy showed good 
eradication rates.87
Conclusions and future perspectives
Hp antibiotic resistance has been increasing all over the world 
in the last decade and this phenomenon constitutes an impor-
tant challenge for the treatment of this fastidious bacterium. 
Low bacterial growth, presence of coccoid forms in distinct 
gastric regions, extremely high resistance rates to various 
antibiotics in local population groups, their inappropriate 
associations, low dosages, or insufficient administration time 
may explain poor therapeutic outcomes. Whether HR might 
affect Hp eradication requires further studies.
Antibiotics once considered a first choice (such as MZ and 
CLA) and included in all therapeutic regimens are declining 
in efficacy because of their extensive use in many areas for 
other infections (eg, MZ in amoebic, gynecological, and 
anaerobic infections and CLA in respiratory diseases).
This has led to an obstinate search for new solutions such 
as the vaccine development and new treatments based on 
the use of natural resources such as plants, probiotics, and 
nutraceuticals.98,99
The search for new antibiotics has a poor therapeutic 
future. Other solutions should be pursued in order to increase 
the cure rate of Hp infection. Nontraditional therapies have 
been indicated as a means to target this important gastric 
pathogen. This approach includes the use of antimicro-
bial peptides (core component of innate immune system 
of numerous eukaryotes) that interact with the anionic 
Gram-negative cell wall because of charge electrostatic 
attractions.100 It also seems reasonable to investigate other 
options aimed at reinforcing the immune system of these 
patients, in order to improve the success rates of Hp infection 
treatment. In addition, novel alternatives based on micro-
organisms, polysaccharides, and intragastric violet light 
irradiation have been proposed.98
The problem of the utility of sensitivity tests is still 
debated. Though undoubtedly useful, sensitivity tests can 
be a challenge, because to be carried out, they need patients’ 
endoscopy, they are expensive, time consuming, and can 
only be performed in few well-equipped laboratories. The 
prevalence of antibiotic resistance for a specific regimen or 
a patient and local data on antibiotic resistance as well as 
eradication patterns have proved to be crucial in the manage-
ment of Hp infections.
The Toronto Consensus suggests to prolong eradication 
therapy up to 14 days replacing the old triple therapy with 
the quadruple therapy based on PPI, bismuth, MZ, and TE 
(PBMT) for most of the patients and alternatively the variant 
quadruple therapy without bismuth: PPI, AMX, MZ, and 
CLA (PAMC).
The new drug vonoprazan has been associated with 
satisfactory eradication rates even in CLA-resistant strains.
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